Eversept Partners LP Makes New Investment in Whitehawk Therapeutics, Inc. $WHWK

Eversept Partners LP purchased a new position in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 260,259 shares of the company’s stock, valued at approximately $630,000. Eversept Partners LP owned about 0.55% of Whitehawk Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Orbimed Advisors LLC acquired a new stake in Whitehawk Therapeutics during the 3rd quarter worth about $7,915,000. Suvretta Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics during the third quarter worth about $7,030,000. Acuta Capital Partners LLC purchased a new stake in Whitehawk Therapeutics in the third quarter valued at approximately $6,480,000. Avoro Capital Advisors LLC acquired a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $5,414,000. Finally, Yu Fan acquired a new position in Whitehawk Therapeutics in the 3rd quarter worth approximately $3,933,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on WHWK. Oppenheimer reissued an “outperform” rating and set a $7.00 target price on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Citizens Jmp assumed coverage on shares of Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 price target on the stock. Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Citigroup assumed coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating for the company. Finally, Weiss Ratings downgraded Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Insiders Place Their Bets

In related news, insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the sale, the insider directly owned 397,106 shares in the company, valued at approximately $1,445,465.84. The trade was a 18.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David James Lennon sold 102,395 shares of the stock in a transaction on Monday, April 6th. The shares were sold at an average price of $3.51, for a total value of $359,406.45. Following the completion of the transaction, the chief executive officer directly owned 691,154 shares of the company’s stock, valued at approximately $2,425,950.54. This represents a 12.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 695,830 shares of company stock worth $2,553,026. Company insiders own 49.90% of the company’s stock.

Whitehawk Therapeutics Trading Up 1.2%

Shares of WHWK opened at $4.22 on Thursday. The firm has a market cap of $208.68 million, a P/E ratio of -2.51 and a beta of 0.77. Whitehawk Therapeutics, Inc. has a 12 month low of $1.57 and a 12 month high of $5.49. The stock’s 50 day moving average is $4.18 and its two-hundred day moving average is $3.39.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.04. Equities research analysts forecast that Whitehawk Therapeutics, Inc. will post -1.44 EPS for the current year.

Whitehawk Therapeutics Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.